The hyperthermic effect of central cholecystokinin is mediated by the cyclooxygenase-2 pathway.

Abstract

Cholecystokinin (CCK) increases core body temperature via CCK2 receptors when administered intracerebroventricularly (icv). The mechanisms of CCK-induced hyperthermia are unknown, and it is also unknown whether CCK contributes to the fever response to systemic inflammation. We studied the interaction between central CCK signaling and the cyclooxygenase (COX) pathway. Body temperature was measured in adult male Wistar rats pretreated with intraperitoneal infusion of the nonselective COX enzyme inhibitor metamizol (120 mg/kg) or a selective COX-2 inhibitor, meloxicam, or etoricoxib (10 mg/kg for both) and, 30 min later, treated with intracerebroventricular CCK (1.7 µg/kg). In separate experiments, CCK-induced neuronal activation (with and without COX inhibition) was studied in thermoregulation- and feeding-related nuclei with c-Fos immunohistochemistry. CCK increased body temperature by ∼0.4°C from 10 min postinfusion, which was attenuated by metamizol. CCK reduced the number of c-Fos-positive cells in the median preoptic area (by ∼70%) but increased it in the dorsal hypothalamic area and in the rostral raphe pallidus (by ∼50% in both); all these changes were completely blocked with metamizol. In contrast, CCK-induced satiety and neuronal activation in the ventromedial hypothalamus were not influenced by metamizol. CCK-induced hyperthermia was also completely blocked with both selective COX-2 inhibitors studied. Finally, the CCK2 receptor antagonist YM022 (10 µg/kg icv) attenuated the late phases of fever induced by bacterial lipopolysaccharide (10 µg/kg; intravenously). We conclude that centrally administered CCK causes hyperthermia through changes in the activity of "classical" thermoeffector pathways and that the activation of COX-2 is required for the development of this response.NEW & NOTEWORTHY An association between central cholecystokinin signaling and the cyclooxygenase-prostaglandin E pathway has been proposed but remained poorly understood. We show that the hyperthermic response to the central administration of cholecystokinin alters the neuronal activity within efferent thermoeffector pathways and that these effects are fully blocked by the inhibition of cyclooxygenase. We also show that the activation of cyclooxygenase-2 is required for the hyperthermic effect of cholecystokinin and that cholecystokinin is a modulator of endotoxin-induced fever.

• Authors: Patrik Keringer, Nora Furedi, Balazs Gaszner, Alexandra Miko, Eszter Pakai, Kata Fekete, Emoke Olah, Leonardo Kelava, Andrej A Romanovsky, Zoltan Rumbus, Andras Garami
• Journal: American journal of physiology. Endocrinology and metabolism (Am J Physiol Endocrinol Metab) Vol. 322 Issue 1 Pg. E10-E23 (01 01 2022) ISSN: 1522-1555 [Electronic] United States
• PMID: 34779255 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cyclooxygenase 2 Inhibitors
• Lipopolysaccharides
• Proto-Oncogene Proteins c-fos
• Receptor, Cholecystokinin B
• lipopolysaccharide, Escherichia coli O111 B4
• Benzodiazepines
• YM 022
• Cholecystokinin
• Cyclooxygenase 2
• Ptgs2 protein, rat

Topics

• Animals
• Anorexia (chemically induced)
• Benzodiazepines (administration & dosage)
• Body Temperature (drug effects)
• Body Temperature Regulation (drug effects)
• Cholecystokinin (administration & dosage, adverse effects)
• Cyclooxygenase 2 (metabolism)
• Cyclooxygenase 2 Inhibitors (administration & dosage)
• Disease Models, Animal
• Eating (drug effects)
• Fever (chemically induced, drug therapy)
• Hyperthermia (chemically induced, metabolism)
• Hypothalamus (drug effects, metabolism)
• Injections, Intraventricular
• Lipopolysaccharides (adverse effects)
• Male
• Proto-Oncogene Proteins c-fos (metabolism)
• Rats
• Rats, Wistar
• Receptor, Cholecystokinin B (antagonists & inhibitors)
• Signal Transduction (drug effects)
• Treatment Outcome